CA2303945A1 - Detection d'une pathologie residuelle minime dans des tumeurs malignes lymphoides - Google Patents
Detection d'une pathologie residuelle minime dans des tumeurs malignes lymphoides Download PDFInfo
- Publication number
- CA2303945A1 CA2303945A1 CA002303945A CA2303945A CA2303945A1 CA 2303945 A1 CA2303945 A1 CA 2303945A1 CA 002303945 A CA002303945 A CA 002303945A CA 2303945 A CA2303945 A CA 2303945A CA 2303945 A1 CA2303945 A1 CA 2303945A1
- Authority
- CA
- Canada
- Prior art keywords
- pcr
- mrd
- probe
- detection
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 36
- 208000007660 Residual Neoplasm Diseases 0.000 title claims abstract description 25
- 230000036210 malignancy Effects 0.000 title claims abstract description 21
- 238000001514 detection method Methods 0.000 title claims description 60
- 239000000523 sample Substances 0.000 claims abstract description 91
- 238000000034 method Methods 0.000 claims abstract description 73
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 33
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 18
- 201000011510 cancer Diseases 0.000 claims abstract description 17
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 14
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 14
- 230000003321 amplification Effects 0.000 claims description 28
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 28
- 108091034117 Oligonucleotide Proteins 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 6
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 33
- 238000003745 diagnosis Methods 0.000 abstract description 24
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 238000012544 monitoring process Methods 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 3
- 230000008707 rearrangement Effects 0.000 description 61
- 238000004458 analytical method Methods 0.000 description 43
- 230000035945 sensitivity Effects 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 35
- 208000032839 leukemia Diseases 0.000 description 31
- 108091008874 T cell receptors Proteins 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 27
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 26
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 24
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 23
- 239000000047 product Substances 0.000 description 19
- 238000009396 hybridization Methods 0.000 description 18
- 238000010790 dilution Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 230000002441 reversible effect Effects 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000001185 bone marrow Anatomy 0.000 description 14
- 239000000975 dye Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 210000005087 mononuclear cell Anatomy 0.000 description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 11
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 230000003211 malignant effect Effects 0.000 description 10
- 230000002285 radioactive effect Effects 0.000 description 9
- 238000002105 Southern blotting Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 238000010222 PCR analysis Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 206010000830 Acute leukaemia Diseases 0.000 description 5
- 208000031404 Chromosome Aberrations Diseases 0.000 description 5
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 231100000005 chromosome aberration Toxicity 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000000824 cytostatic agent Substances 0.000 description 4
- 230000001085 cytostatic effect Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000011419 induction treatment Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 238000009093 first-line therapy Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000011418 maintenance treatment Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000011897 real-time detection Methods 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 description 2
- 101150097493 D gene Proteins 0.000 description 2
- 101100285402 Danio rerio eng1a gene Proteins 0.000 description 2
- 101150014361 Delta gene Proteins 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 206010061819 Disease recurrence Diseases 0.000 description 2
- 101000891113 Homo sapiens T-cell acute lymphocytic leukemia protein 1 Proteins 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 101100179469 Mus musculus Ighg2b gene Proteins 0.000 description 2
- 101000702553 Schistosoma mansoni Antigen Sm21.7 Proteins 0.000 description 2
- 101000714192 Schistosoma mansoni Tegument antigen Proteins 0.000 description 2
- 102100040365 T-cell acute lymphocytic leukemia protein 1 Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000013394 immunophenotyping Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108010037497 3'-nucleotidase Proteins 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 1
- 108050002855 Histone-lysine N-methyltransferase 2A Proteins 0.000 description 1
- 101000840257 Homo sapiens Immunoglobulin kappa constant Proteins 0.000 description 1
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
- 102100029572 Immunoglobulin kappa constant Human genes 0.000 description 1
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000034809 Product contamination Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700042082 T-Cell Receptor gamma Genes Proteins 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000011184 adult acute lymphocytic leukemia Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000003583 cytomorphological effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 208000012318 pareses Diseases 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 238000003322 phosphorimaging Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011336 routine blood sampling Methods 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Cette invention porte sur le diagnostic du cancer, et plus spécifiquement sur le contrôle du développement pathologique pendant et après traitement. Cette invention porte donc sur un procédé de détermination d'une pathologie résiduelle minime, ce procédé consistant à amplifier les molécules d'acide nucléique à l'aide d'au moins une amorce réagissant avec un segment génique commun, et à identifier des séquences d'acide nucléique spécifiques de la tumeur maligne en effectuant une hybridation avec une sonde fluorogène réagissant spécifiquement et sélectivement avec des séquences d'acide nucléique spécifiques de la tumeur maligne.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97202858 | 1997-09-18 | ||
| EP97202858.3 | 1997-09-18 | ||
| PCT/NL1998/000542 WO1999014366A2 (fr) | 1997-09-18 | 1998-09-18 | Detection d'une pathologie residuelle minime dans des tumeurs malignes lymphoides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2303945A1 true CA2303945A1 (fr) | 1999-03-25 |
Family
ID=8228734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002303945A Abandoned CA2303945A1 (fr) | 1997-09-18 | 1998-09-18 | Detection d'une pathologie residuelle minime dans des tumeurs malignes lymphoides |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1015635A2 (fr) |
| AU (1) | AU9190098A (fr) |
| CA (1) | CA2303945A1 (fr) |
| WO (1) | WO1999014366A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3103140A1 (fr) * | 2018-06-11 | 2019-12-19 | Monoquant Pty Ltd | Procede d'amplification |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991015600A1 (fr) * | 1990-03-30 | 1991-10-17 | City Of Hope | Detection de maladies residuelles imperceptibles dans des malignites lymphoides |
| AU9147991A (en) * | 1990-11-28 | 1992-06-25 | University Of Texas System, The | Methods and compositions for detecting and quantitating hematopoietic tumors |
| US5538848A (en) * | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| AU693023B2 (en) * | 1995-05-05 | 1998-06-18 | Applied Biosystems, Llc | Methods and reagents for combined PCR amplification and hybridization probing assay |
| CA2227826C (fr) * | 1995-07-27 | 2009-07-07 | Dalgety Plc | Procede de determination du genotype de couleur de robe d'un porc |
-
1998
- 1998-09-18 CA CA002303945A patent/CA2303945A1/fr not_active Abandoned
- 1998-09-18 WO PCT/NL1998/000542 patent/WO1999014366A2/fr not_active Ceased
- 1998-09-18 AU AU91900/98A patent/AU9190098A/en not_active Abandoned
- 1998-09-18 EP EP98944341A patent/EP1015635A2/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999014366A3 (fr) | 1999-05-06 |
| AU9190098A (en) | 1999-04-05 |
| EP1015635A2 (fr) | 2000-07-05 |
| WO1999014366A2 (fr) | 1999-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pongers-Willemse et al. | Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes | |
| Pallisgaard et al. | Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real‐time RT‐PCR exemplified by t (12; 21) TEL‐AML1 fusion transcript | |
| Verhagen et al. | Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia | |
| Lawler et al. | Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction | |
| Downing et al. | An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8; 21)(q22; q22) translocation | |
| Yokota et al. | Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients | |
| Dippel et al. | Clonal T‐cell receptor γ‐chain gene rearrangement by PCR‐based GeneScan analysis in advanced cutaneous T‐cell lymphoma: a critical evaluation | |
| Ugozzoli et al. | Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation | |
| Miyauchi et al. | Mutations of the N-ras gene in juvenile chronic myelogenous leukemia | |
| US20080108509A1 (en) | Process for Recognizing Signatures in Complex Gene Expression Profiles | |
| Dölken et al. | Quantitative detection of t (14; 18)-positive cells by real-time quantitative PCR using fluorogenic probes | |
| US20090253583A1 (en) | Hematological Cancer Profiling System | |
| US20200017915A1 (en) | Methods and compositions for determining responsiveness to antibody therapy | |
| US5024934A (en) | Detection of minimal numbers of neoplastic cells carrying DNA translocations by DNA sequence amplification | |
| Veelken et al. | Sensitive detection of clonal antigen receptor gene rearrangements for the diagnosis and monitoring of lymphoid neoplasms by a polymerase chain reaction-mediated ribonuclease protection assay | |
| Luthra et al. | Real-time 5′→ 3′ exonuclease-based PCR assay for detection of the t (11; 14)(q13; q32) | |
| Liang et al. | Multiplex RT‐PCR assay for the detection of major fusion transcripts in Taiwanese children with B‐lineage acute lymphoblastic leukemia | |
| Saffroy et al. | Real‐time quantitation of bcr‐abl transcripts in haematological malignancies | |
| Yin | Minimal residual disease in acute myeloid leukaemia | |
| Hosler et al. | Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma | |
| CA2303945A1 (fr) | Detection d'une pathologie residuelle minime dans des tumeurs malignes lymphoides | |
| Jorgensen et al. | Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications | |
| Vshyukova et al. | Expression of aberrantly spliced oncogenic Ikaros isoforms coupled with clonal IKZF1 deletions and chimeric oncogenes in acute lymphoblastic leukemia | |
| Sholl et al. | Molecular Analysis of Genetic Markers for Non‐Hodgkin Lymphomas | |
| Cazzaniga et al. | Monitoring minimal residual disease using chromosomal translocations in childhood ALL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |